Zinzino group revenue increased with a total of 6% in Q4 and 5% for the full year 2022, compared with the previous year.
The revenue in December for Zinzino's sales markets decreased by 16% and amounted to SEK 120.2 (143.8) million. Faun Pharma's external sales decreased by 4% and amounted to SEK 5.0 (5.2) million. Overall, the Group decreased revenues by 16% to SEK 125.2 (149.0) million compared with the previous year.
Sales in Zinzino's sales markets increased by 6% in the fourth quarter of 2022 compared with the same period last year and amounted to SEK 409.7 (386.1) million. Total revenues in the Group increased by 6% in the fourth quarter and amounted to SEK 425.5 (401.2) million.
Accumulated revenue for January - December 2022 increased by 5% compared with the same period last year and amounted to SEK 1439.3 (1370.6) million.
Revenues were distributed as follows:
| Regions, mSEK | 22-dec | 21-dec | Change | Q4 2022 | Q4 2021 | Change | YTD 2022 | YTD 2021 | Change |
|
The Nordics |
31.0 |
36.4 |
-15% |
87.7 |
98.9 |
-11% |
323.4 |
369.8 |
-13% |
| Central Europe |
27.6 |
27.5 |
0% |
94.1 |
70.2 |
34% |
290.6 |
232.7 |
25% |
| East Europe |
27.1 |
32.2 |
-16% |
103.5 |
99.1 |
4% |
341.3 |
337.1 |
1% |
|
South & West Europe |
14.8 |
16.8 |
-12% |
50.5 |
44.2 |
14% |
164.5 |
147.1 |
12% |
|
The Baltics |
7.1 |
10.4 |
-32% |
25.2 |
27.0 |
-7% |
77.8 |
79.2 |
-2% |
| North America |
5.7 |
6.1 |
-7% |
25.2 |
15.2 |
66% |
77.2 |
51.3 |
50% |
| Asia-Pacific |
5.6 |
13.9 |
-60% |
19.6 |
30.4 |
-36% |
77.3 |
89.7 |
-14% |
| Africa |
1.3 |
0.5 |
160% |
3.9 |
1.1 |
255% |
10.1 |
1.1 |
818% |
| Zinzino | 120.2 | 143.8 | -16% | 409.7 | 386.1 | 6% | 1362.2 | 1308.0 | 4% |
|
Faun Pharma |
5.0 |
5.2 |
-4% |
15.8 |
15.1 |
5% |
77.1 |
62.6 |
23% |
| Zinzino Group | 125.2 | 149.0 | -16% | 425.5 | 401.2 | 6% | 1439.3 | 1370.6 | 5% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
marketing@zinzino.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 11:00 the 4th of January 2023.
Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, the US and Australia.
https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-2022,c3693147
https://mb.cision.com/Main/10976/3693147/1763641.pdf
(c) 2023 Cision. All rights reserved., source Press Releases - English
ZINZINO AB 
